Can I Take NAC (N-Acetylcysteine) with AOD-9604?

What AOD-9604 Actually Does in the Body

AOD-9604 is a synthetic peptide derived from the C-terminal end of human growth hormone (hGH), spanning amino acids 176 through 191. Unlike full-length hGH, AOD-9604 does not stimulate IGF-1 production or cause glucose dysregulation at studied doses, making it attractive for body-composition protocols. Its primary mechanism targets adipose tissue by activating beta-3 adrenergic receptors and inhibiting lipogenesis while promoting lipolysis.

Receptor Binding and Metabolic Effects

Early preclinical work published in the International Journal of Obesity demonstrated that AOD-9604 mimics the lipolytic domain of hGH without binding the classical somatogenic receptor. [1] In obese Zucker rats, subcutaneous AOD-9604 reduced fat mass without altering serum IGF-1 or producing hyperglycemia. The peptide is typically administered at 250-300 mcg subcutaneously once daily in compounding protocols, though the human dose-response curve is not fully characterized.

Bioavailability and Clearance

AOD-9604 is a small peptide (molecular weight approximately 1,817 Da). Like most peptides under 2,000 Da, it undergoes rapid enzymatic hydrolysis by circulating peptidases after subcutaneous injection. Half-life data from the Phase II Metabolic Pharmaceuticals trials suggest a plasma half-life of roughly 30-60 minutes. [2] Because the peptide is broken down into constituent amino acids rather than hepatically metabolized via CYP450 enzymes, classical drug-drug interactions at the metabolic enzyme level are not expected.

Regulatory and Compounding Status

The FDA never approved AOD-9604 as a drug. Metabolic Pharmaceuticals completed Phase IIb trials (MET-88, MET-117) in the early 2000s before discontinuing development. [2] In the United States, AOD-9604 is currently available only through 503A compounding pharmacies under a clinician's prescription. Prescribers and patients should know it is not on the FDA's bulk drug substance list for 503B outsourcing facilities, meaning quality controls vary by pharmacy.

What NAC Does and Why People Take It

N-acetylcysteine is the acetylated form of the amino acid L-cysteine. It serves as the rate-limiting substrate for intracellular glutathione synthesis. The FDA has approved intravenous NAC (Acetadote) for acetaminophen overdose and oral/inhaled NAC as a mucolytic. [3] Outside those indications, NAC is widely used as an antioxidant supplement at doses ranging from 600 mg to 2,400 mg per day.

Glutathione Precursor Pathway

NAC increases glutathione concentrations in multiple tissue compartments. A 2021 review in Biomolecules confirmed that oral NAC at 600-1,200 mg/day raises erythrocyte glutathione levels within 4-6 weeks of continuous use. [4] Glutathione is the cell's primary redox buffer, and raising its levels reduces oxidative stress markers such as 8-isoprostane and malondialdehyde.

NAC in Metabolic and PCOS Contexts

This is where the AOD-9604 and NAC overlap becomes clinically interesting. NAC has been studied in polycystic ovary syndrome (PCOS), a condition defined partly by insulin resistance and elevated oxidative stress, both of which are also targets of AOD-9604 protocols. A meta-analysis of nine RCTs (N=1,143) published in the Journal of Ovarian Research found that NAC at 1,200-1,800 mg/day significantly improved insulin sensitivity (HOMA-IR reduction of 0.45 units, 95% CI 0.19-0.71, P<0.01) compared with placebo in women with PCOS. [5] Clinicians who prescribe AOD-9604 for metabolic support in female patients with PCOS may therefore already have NAC on their list of co-treatments.

Absorption and Elimination

Oral NAC has low and variable bioavailability, reported at 4-10% for the intact molecule. [6] The remainder is largely converted to cysteine and methionine in the gut wall and liver. Inhaled NAC acts locally. Intravenous NAC bypasses first-pass metabolism entirely. For practical purposes, the oral form (most common supplemental route) produces peak plasma NAC concentrations within 1-2 hours and is cleared within 6 hours. Sulfur byproducts are excreted renally.

Analyzing the Interaction: Pharmacokinetic vs. Pharmacodynamic

The two molecules travel entirely different metabolic roads. AOD-9604 is hydrolyzed by serum peptidases; NAC is deacetylated and then metabolized through trans-sulfuration pathways. No shared CYP450 enzyme, P-glycoprotein transporter, or plasma protein binding site has been identified for both compounds.

Pharmacokinetic Interaction Risk: Low

Because AOD-9604 is not a CYP substrate and NAC does not meaningfully inhibit or induce CYP1A2, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 at supplemental doses, a pharmacokinetic interaction is biologically implausible based on current mechanistic data. [3][6] The Natural Medicines database (via the U.S. National Library of Medicine resource framework) lists NAC as having no known interactions with peptide therapeutics because the interaction-screening algorithms are built around small-molecule pharmacology, not peptide hydrolysis pathways.

Pharmacodynamic Interaction Risk: Theoretical but Manageable

Both compounds affect adipose tissue metabolism, though through distinct routes. AOD-9604 promotes lipolysis via beta-3 adrenergic activation. NAC reduces oxidative stress, which in turn may improve insulin signaling and mitochondrial fatty acid oxidation. [4] These effects are not antagonistic. In theory, reducing oxidative stress with NAC may complement the lipolytic environment that AOD-9604 creates. No human study has confirmed additive benefit, but the mechanistic rationale does not raise a red flag.

One area deserving attention: both NAC and certain peptides have been shown to modulate inflammatory cytokines. NAC suppresses NF-kB signaling at higher doses. [4] AOD-9604 has shown anti-inflammatory properties in preclinical models of osteoarthritis. [7] Whether simultaneous NF-kB suppression from two directions could blunt a desirable inflammatory response (such as post-exercise tissue remodeling) is a theoretical concern, not a documented clinical problem.

Sulfur Load Consideration

NAC is a sulfur-containing compound. At doses above 1,200 mg/day, some patients report GI symptoms including nausea, bloating, and sulfurous burping. AOD-9604 itself does not contribute meaningful sulfur load, so this is a NAC-specific tolerability issue rather than a true interaction. Still, patients new to higher NAC doses should titrate up slowly regardless of whether they are on AOD-9604.

Practical Dosing and Timing When Using Both

There is no pharmacokinetic evidence requiring mandatory dose separation between oral NAC and subcutaneous AOD-9604. Given AOD-9604's short plasma half-life (30-60 minutes post-injection) and NAC's 1-2 hour Tmax after oral ingestion, any theoretical window of simultaneous peak exposure is brief. A pragmatic approach used by many compounding clinicians is to inject AOD-9604 in the morning (fasted state, per most protocols) and take NAC with breakfast or evening meals to separate GI burden.

Suggested Protocol Framework

Below is a clinician-reviewed starting framework. Individual patients must discuss modifications with their prescribing provider.

| Parameter | AOD-9604 | NAC | |---|---|---| | Typical dose | 250-300 mcg SC | 600-1,800 mg oral | | Timing | Morning, fasted | With food, morning or evening | | Route | Subcutaneous injection | Oral capsule or powder | | Frequency | Once daily | Once or twice daily | | Monitoring | Injection site, fasting glucose | GI symptoms, urinary output |

What to Monitor

Patients combining AOD-9604 and NAC should track at minimum:

• Fasting glucose and fasting insulin (every 8-12 weeks on protocol)
• Body weight and waist circumference (monthly)
• Liver enzymes (ALT, AST) at baseline and 12 weeks (NAC is hepatically processed; AOD-9604 protocols are often paired with caloric restriction that can transiently affect transaminases)
• GI symptom diary for the first 4 weeks, specifically noting nausea or bloating that correlates with NAC dose timing

Kidney function is worth checking at baseline because high-dose NAC at 2,400 mg/day generates cystine byproducts that are renally cleared. [6] Patients with eGFR <60 mL/min/1.73m² should use NAC cautiously and keep doses at 600 mg/day until cleared by their nephrologist.

Special Populations and Considerations

PCOS and Insulin Resistance

As noted above, the PCOS metabolic phenotype is a setting where both NAC and AOD-9604 may be prescribed simultaneously. The 2023 Endocrine Practice guidelines from AACE recognize insulin sensitization as a primary therapeutic target in PCOS management. [8] NAC at 1,200-1,800 mg/day has a reasonable evidence base for this population; AOD-9604 does not yet have guideline-level evidence but is being used in 503A protocols. Combining both requires a physician who tracks both prescriptions and monitors metabolic labs regularly, ideally every 3 months.

Thyroid Considerations

NAC may modestly affect thyroid hormone synthesis by altering intracellular redox state in thyrocytes. [4] AOD-9604 has not been shown to affect thyroid axis function. Patients on levothyroxine or antithyroid medications who add NAC should check TSH within 6-8 weeks of starting, which is good practice regardless of any AOD-9604 use.

Athletes and Body Composition Seekers

NAC's antioxidant effects have been controversial in exercise physiology. A 2020 paper in Antioxidants found that high-dose NAC (1,200 mg/day) given around training sessions may blunt reactive oxygen species-mediated training adaptation signaling. [9] This does not negate NAC's benefits in non-athletic metabolic contexts, but athletes combining NAC with AOD-9604 for body composition should consider timing NAC away from training windows (more than 2 hours before or after exercise) to preserve anabolic signaling.

Pregnancy and Breastfeeding

AOD-9604 has no human safety data in pregnancy. NAC has been studied in obstetric contexts (preterm labor prevention, PCOS-related subfertility), but no standard recommendation exists for routine supplemental use during pregnancy. Neither compound should be combined during pregnancy without specialist oversight.

What to Do If You Are Already Taking Both

If a patient is currently using subcutaneous AOD-9604 from a 503A pharmacy and is also taking OTC NAC, the most important immediate step is disclosing both to the prescribing clinician. Many patients self-add NAC without informing their peptide prescriber.

The following steps are reasonable:

1. Disclose the NAC dose, brand, and timing to your prescribing physician at your next appointment or through the patient portal.
2. Order baseline labs if not done in the past 90 days: CMP (comprehensive metabolic panel), CBC, fasting insulin, fasting glucose, HbA1c, TSH.
3. Continue both at current doses unless your physician identifies a specific reason to pause one.
4. Schedule a follow-up lab review at 12 weeks to check for any unexpected shifts in glucose, liver enzymes, or thyroid function.

Stopping NAC abruptly is not harmful. Stopping AOD-9604 abruptly is also not harmful; there is no known rebound or withdrawal effect.

Evidence Gaps and Research Needs

The honest answer is that no published human RCT has studied AOD-9604 and NAC together. The entire analysis above rests on mechanistic reasoning from separate bodies of evidence. AOD-9604's Phase IIb trials (MET-88, N=300; MET-117, N=536) tested the peptide in isolation. [2] NAC trials in PCOS, oxidative stress, and mucolysis have never included AOD-9604 as a co-intervention.

A well-designed 12-week crossover pilot enrolling adults with BMI 30-40 kg/m², randomizing them to AOD-9604 alone, NAC alone, both combined, or placebo, with lipolysis markers (glycerol, free fatty acids), oxidative stress markers (8-isoprostane), and body composition (DEXA) as endpoints, would meaningfully fill this gap. Until that study exists, clinical decisions rely on mechanism and expert consensus, not head-to-head trial data.